Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD3 | P35462 | 3/20 | 0.85 |
| ▸ | HTR1A | P08908 | 1/20 | 0.67 |
| ▸ | DRD2 | P14416 | 1/20 | 0.60 |
| ▸ | FYN | P06241 | 1/20 | 0.53 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8688812 | 0.92 | DRD3 (1.00) | DRD3HTR1ADRD2FYNSIGMAR1 | |
| SCHEMBL12006562 | 0.88 | DRD3 (0.70) | DRD3HTR1ADRD2SIGMAR1 | |
| SCHEMBL9285858 | 0.82 | DRD3 (0.74) | DRD3HTR1ADRD2FYNSIGMAR1 | |
| SCHEMBL4047168 | 0.81 | DRD3 (0.77) | DRD3HTR1ADRD2FYNSIGMAR1 | |
| SCHEMBL28699255 | 0.81 | DRD3 (0.77) | DRD3HTR1ADRD2FYN | |
| SCHEMBL9359278 | 0.80 | HTR1A (1.00) | DRD3HTR1ADRD2 | |
| SCHEMBL31558065 | 0.80 | HTR1A (1.00) | DRD3HTR1ADRD2 | |
| SCHEMBL29362760 | 0.80 | DRD3 (0.75) | DRD3HTR1ADRD2 | |
| Hydrochloric Acid SCHEMBL29064041 | 0.79 | HTR1A (0.97) | DRD3HTR1ADRD2 | |
| SCHEMBL20257791 | 0.78 | DRD3 (0.69) | DRD3HTR1ADRD2SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2427425-B1 | TETRACYCLINE COMPOUNDS | TETRAPHASE PHARMACEUTICALS INC (US) | 2017-03-08 | — | — | EP | disclosed |
| US-9315451-B2 | Tetracycline compounds | TETRAPHASE PHARMACEUTICALS, INC. (US) | 2016-04-19 | — | — | US | disclosed |
| US-20120135968-A1 | Tetracycline Compounds | TETRAPHASE PHARMACEUTICALS, INC. | 2012-05-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120135968-A1 | Tetracycline Compounds | TUBB, TUBA1C, TUBA1A | DRD3 3818/4885HTR1A 2762/4885DRD2 4124/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.